Article Versions Notes

Semo D, Obergassel J, Dorenkamp M, Hemling P, Strutz J, Hiden U, Müller N, Müller UA, Zulfikar SA, Godfrey R, et al. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of Clinical Medicine. 2023; 12(4):1356. https://doi.org/10.3390/jcm12041356

Semo, Dilvin, Julius Obergassel, Marc Dorenkamp, Pia Hemling, Jasmin Strutz, Ursula Hiden, Nicolle Müller, Ulrich Alfons Müller, Sajan Ahmad Zulfikar, Rinesh Godfrey, and et al. 2023. "The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms" Journal of Clinical Medicine 12, no. 4: 1356. https://doi.org/10.3390/jcm12041356

Semo, D., Obergassel, J., Dorenkamp, M., Hemling, P., Strutz, J., Hiden, U., Müller, N., Müller, U. A., Zulfikar, S. A., Godfrey, R., & Waltenberger, J. (2023). The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. Journal of Clinical Medicine, 12(4), 1356. https://doi.org/10.3390/jcm12041356